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Abstract
Effective inhibitors of invasion and metastasis represent a serious unmet clinical need. We
have recently identified 4-fluoro-3’,4’,5’-trimethoxychalcone or C16 as a potent anti-invasive
molecule. In this paper, we report on the development of an optimized vehicle for oral admin-
istration of C16. We also explore its pharmacokinetic and toxicity profile in rodents as a pre-
lude to a broad-scope evaluation as a pharmacological tool in animal models of disease.
C16 showed suboptimal pharmacokinetics with limited oral bioavailability and whole blood
stability. Rapid metabolism with elimination via glutathione conjugation was observed. An
oral dosing routine using medicated gels was developed to overcome bioavailability issues
and yielded sustained whole blood levels above the half maximal effective concentration
(EC50) in a 7-day study. The compound proved well-tolerated in acute and chronic experi-
ments at 300 mg/kg PO dosing. The medicated gel formulation is highly suitable for evalua-
tion of C16 in animal models of disease.
Introduction
In the malignant progression of a solid tumor the gain of an invasive phenotype is the first and
a necessary step in the development of metastases [1,2]. The sequelae of metastasis account for
90% of cancer-related mortality. To date, the biological events underlying invasion and metas-
tasis remain poorly understood [3]. The development of effective anti-invasive/antimetastatic
tools and drugs is therefore an unmet clinical need [4].
Our laboratories have been characterizing and validating 4-fluoro-3’,4’,5’-trimethoxychal-
cone or C16 as a novel invasion inhibitor for the study and potential treatment of metastatic
cancer (Fig 1) [5]. C16 has nanomolar anti-invasive potency in the chick heart [6] and Matrigel
in vitro invasion models against several human cancer cell lines (MCF-7/6 breast cancer, BLM
melanoma and SK-OV-3 ovarian carcinoma). The molecule shows a defined structure-activity
relationship [7–9] and possesses adequate in vitro absorption, distribution, metabolism, and
excretion (ADME) properties (see section ‘Stability and metabolism’ and [5]). Given its discov-
ery in a phenotypic model, the biological target of C16 is unknown. We have differentiated the
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molecular mechanism of action of C16 from that of other antimetastatic agents [10], and are
currently characterizing its biochemical interactions in detail.
The aim of the present research was to explore the drug metabolism and pharmacokinetics
(DMPK) and toxicity profile of C16 in rodents, in preparation of an evaluation of its efficacy
as a pharmacological tool in animal models of disease. Here, we have developed appropriate
vehicles to accommodate the low bioavailability of C16, including a formulation as a medi-
cated gel suitable for chronic oral dosing. Furthermore, we have analyzed the pharmacokinetic
properties and metabolism of C16, as well as its maximum tolerated dose and repeat-dose tox-
icity profile. Routine pharmacokinetics (PK) and metabolite profiling was conducted in the
rat. Additional PK evaluation as well as tolerability and toxicity testing was performed in the
mouse, as this species will be used in future proof of efficacy studies.
C16 is a chalcone, a chemical class to which various biological activities have been attrib-
uted, albeit often at high concentrations [11,12]. Despite this body of literature, follow-up stud-
ies on the DMPK properties of these molecules are rare [13,14], and it thus often remains
unclear whether sufficiently high plasma levels can be obtained for a sustained period in order
to assess in vivo actions. The present study may therefore have relevance to research on other
members of the chalcone chemical class.
Materials and methods
Additional protocols are available in S1 File.
Statistics
Data was processed using IBM SPSS Statistics 23 or higher. All data were tested for normality
(Shapiro-Wilk test) and homogeneity of variances (homoscedasity, Levene’s test). If both con-
ditions were met, a one-way ANOVA with post-hoc Tukey hsd was conducted. If the data was
not normally distributed, then a non-parametric Kruskal-Wallis H test or Mann-Whitney U
test was performed. If the data was not homoscedastic, Welch’s t-test and a post-hoc Gamess-
Howell test were conducted.
Animal welfare
All aspects of this work related to in vivo experiments, including housing, experimentation,
and animal disposal were performed in general accordance with the Guide for the Care and
Use of Laboratory Animals (Eighth Edition) [15]. Relevant protocols were approved by the
Committee on the Ethics of Animal Experiments of Ghent University (Permit Number: ECD
15/59). The persons who carried out the described experiments received appropriate training
in animal care and handling. Animal numbers were kept low due to the exploratory nature of
the study. Exact numbers were based on relevant literature work using similar or identical ani-
mal studies. Animal health was monitored as indicated in the individual protocols, including
during every animal manipulation. Throughout all studies, the following criteria were used to
remove an animal from the study and humanely euthanize to prevent undue pain or distress:
inability to eat and/or drink, inability to thermoregulate, weight loss (>20%), moribund con-
dition, prolonged bleeding, seizures, paralysis. These endpoints were not reached. No unex-
pected deaths occurred in any of the described studies. Animals were euthanized by CO2,
except for those that underwent cardiac exsanguination after Avertin anesthesia. Analgesics or
anesthesia were administered as indicated in the individual protocols.
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Chemicals
C16 was prepared as described earlier [5]. A tribromoethanol injectable solution (Avertin) was
prepared as described in Section E in S1 File. In-house prepared Milli-Q water was used. Cre-
mophor EL (Sigma, Germany), corn oil (Wako, Japan), dimethyl sulfoxide (DMSO, Sigma-
Aldrich, Germany) anhydrous N,N-dimethylacetamide (DMA, Wako, Japan), ethanol (Merck,
Germany), Medigel Sucralose (2 oz cups, ClearH2O, USA), 2-methyl-2-butanol (amylene
hydrate, Sigma-Aldrich, Germany) 1,2-propanediol (propylene glycol, PG) (Wako, Japan),
polyethylene glycol (PEG) 400 (Sigma, U.S.A), PEG 600 (Alfa Aesar, Great Britain or Sigma,
USA), sodium heparin (5000 units/mL injectable solution, LEO Pharma, Belgium) Solutol HS-
15 (BASF, Germany) 2,2,2-tribromoethanol (Sigma-Aldrich, Germany) were used as obtained
from the indicated suppliers.
Vehicle development
Nephelometry. The solubility of C16 was tested at 10 and 30 mg/mL for the indicated
vehicles using laser nephelometry in 96-well plates (BMG LabTech NEPHELOstar microplate
reader, BMG LabTech, USA). Solutions were prepared using solubilizing techniques including
Fig 1. Structure and biological activity of C16.
https://doi.org/10.1371/journal.pone.0192548.g001
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sonication, heating up to 37 ˚C and vortex. Solubility data was categorized as soluble (result
+15 of blank), slightly soluble (result between +15 and +25 of blank) or not soluble (result >
+25 of blank) [16].
Preparation of a C16 solution in 20% DMSO / 10% (DMSO / Cremophor EL 1:1) / 70%
H2O. For a 2 mg/mL final concentration, 240 μL of DMSO was added to 2.4 mg of C16 in a
glass vial. The mixture was vortexed resulting in a clear solution. Of this stock solution, 210 μL
was mixed with 105 μL of a 1:1 DMSO / Cremophor EL mixture and 735 μL of water, yielding
a clear solution.
Preparation of a C16 solution in 10% Solutol HS-15 / 90% PEG 600. Solutol HS15 and
PEG 600 were warmed to 37 ˚C. The pre-calculated volume of Solutol HS15 was added to C16.
The mixture was vortexed and then kept at 37 ˚C with sonication until C16 had completely
dissolved. PEG 600 was then slowly added and the mixture was vortexed again, whereupon the
solution was visually clear. Solutions up to 30 mg/mL were prepared in this way.
Stability test of C16 in 10% Solutol HS -15 / 90% PEG 600. Solutions of 30 mg/mL and
10 mg/mL of C16 were prepared and stored at room temperature and 4˚C for 24 h. The stabil-
ity of C16 was evaluated at 0, 1, 2, 4, 8 and 24 h after formulation by high-performance liquid
chromatography-mass spectrometry/mass spectrometry (HPLC-MS/MS) (electrospray ioniza-
tion, ESI+) analysis using oxybutynin as an internal standard (IS). Analyte samples were
diluted 500x with acetonitrile (ACN)/H2O (20:80). This solution was further diluted 100x with
an oxybutynin solution (1 ng/μL in ACN/H2O 20:80), giving a final concentration of 0.6 ng/μL
and 0.2 ng/μL, respectively, for HPLC-MS/MS analysis (multiple reaction monitoring scan
mode, MRM, see Section A of S1 File for more details). All analyses were performed in
triplicates.
Preparation of C16-doped medicated gel. A pre-weighed amount of C16 was dissolved
in 1 mL of DMSO and the resulting solution was delivered into a cup of Medigel sucralose
(pre-warmed to room temperature) with a syringe through the foil lid. In order to facilitate
even distribution of C16 in the gel, the injection was spread over several points. The resulting
suspension of C16 in gel was dispersed evenly by vigorous shaking for at least two minutes.
Visual control confirmed a uniform and finely dispersed suspension of C16 particles in the gel.
The final DMSO concentration in the gel was 1.64%.
Tolerability test of vehicles. Vehicles of 10% Solutol HS-15 / 90% PEG 600 and 10%
DMA / 90% PEG 600 were evaluated for tolerability by oral gavage at 10 mL/kg using the same
protocol as for the single dose per os (PO) maximum tolerated dose (MTD) study (see below).
The tolerability of DMSO-doped medicated gel was evaluated during the repeat-dose toxicity
test.
PK studies
Plasma PK study (IV and PO) in male Sprague-Dawley rats. Six male Sprague-Dawley
rats (200–350 g) were obtained from Hilltop Labs. Animals were assigned randomly to two
groups (IV or PO) of 3 upon arrival. Duration of acclimation was approximately two days.
Animals were healthy at the start of the trial.
Animals subjected to IV dosing were fitted with a jugular vein cannula (JVC) under isoflur-
ane anesthesia (induction 4%, maintenance 2.0%, oxygen 1 L/min) and under an external heat-
ing source. Post-operative analgesia was provided in the form of 2.5–5 mg/kg of ketoprofen
subcutaneously. Benzylpenicillin (60 mg) was given intramuscularly to prevent infection. Ster-
ile 0.9% NaCl was injected subcutaneously under the back skin using a 21G needle during
recovery to replace fluid loss. Animals were placed under a heat lamp and monitored until
they regained full consciousness. Animals were returned to a sterile cage in the animal care
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room only after full recovery and when exhibiting normal behavior. Surgically modified ani-
mals were housed individually, monitored hourly for the first 4 h and then daily over a 2-day
recovery period.
Animals were maintained in a well-controlled temperature (20–24˚C) and humidity (30%-
70%) environment with 12 h light/dark cycles. Conventional cages with wood chip bedding
were used. Animals were identified by a cage label. The study was not blinded. Food was with-
held from all animals for a minimum of twelve hours prior to test article administration and
returned at approximately 4 h post-dose. Water was supplied ad libitum.
C16 was dosed in cassette with two undisclosed compounds of similar chemical structure.
Dosing solutions were prepared in 100% DMSO on the day of dosing. The concentration of
C16 was 1 and 5 mg/mL for IV and PO dosing, respectively. C16 was administered at 1 mg/kg
IV via JVC or at 10 mg/kg PO.
Sampling took place pre-dose, 5, 15, 30 min, 1, 2, 4, and 8 h post-dose. Blood samples (0.3
mL) were collected via the JVC, placed into chilled tubes containing sodium heparin and kept
on ice until centrifugation. Plasma preparation involved centrifugation at a temperature of 2
to 8˚C at 3,000 g for 5 min. Plasma samples were stored frozen at -70˚C until analysis. No nec-
ropsy was performed.
Whole-blood PK study (IV, IP and PO) in male CD-1 mice. Nine male CD-1 mice (25–
35 g) were obtained from Hilltop Labs. Duration of acclimation was at least two days. Animals
were randomly assigned to the three dose groups (IV, PO, intraperitoneal (IP), N = 3 per
group), healthy at the start of the trial, housed one per cage (conventional type with wood chip
bedding material), identified by a cage label and maintained in a well-controlled temperature
(20–24 C) and humidity (30%-70%) environment with 12 h light/dark cycles. Animals
intended for IV dosing were fitted with a jugular vein cannula (JVC, procedure see rat plasma
PK study above). The study was not blinded. Food was withheld from the animals for a mini-
mum of 12 h prior to test article administration until 4 h post-dose. Water was offered ad
libitum.
C16 was dosed in cassette together with two undisclosed compounds of similar chemical
structure. The dose of each test article was 1 mg/kg (IV, JVC, 0.5 mg/mL) or 10 mg/kg (IP and
PO gavage, 2 mg/mL). Two respective dosing solutions were prepared (protocol see above)
containing 0.5 and 2 mg/mL of C16 (and equal concentrations of the other two test articles) in
20% DMSO / 10% (DMSO / Cremophor EL 1:1) / 70% H2O. Formulations were prepared one
day prior to dosing and stored at 4 ˚C.
Blood samples were taken pre-dose and 5 (except for PO administration), 15, 30 min, 1, 2,
4, and 8 h after dosing. The samples were collected via the tail vein or by cardiac puncture (8 h
time point). Blood (25 μL) was collected and pipetted into a tube with 25 μL heparinized water
(1 μL of sodium heparin (1000 unit/ml) + 24 μL water) within 30 seconds of collection. The
sample was pipetted up and down five times, immediately frozen on dry ice and stored at
-60˚C to -80˚C until analyzed. No necropsy was performed.
Data processing. Pharmacokinetic parameters were estimated by a non-compartmental
model using WinNonlin (v5.2.1 or higher) software. The maximum plasma/blood concentra-
tions (c0) after IV dosing were estimated by extrapolation of the first two time points back to
t = 0. The maximum blood concentration (cmax) and the time to reach maximum blood drug
concentration (tmax) after PO dosing were derived from the data. The area under the time-con-
centration curve (AUC) was calculated using the linear trapezoidal rule with calculation to the
last quantifiable data point, and with extrapolation to infinity if applicable. Plasma/blood half-
life (t1/2) was calculated from 0.693/slope of the terminal elimination phase. Mean residence
time (MRT) was calculated by dividing the area under the moment curve (AUMC) by the
AUC. Clearance (CL) was calculated from dose/AUC. Steady-state volume of distribution
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(Vss) was calculated from CLMRT. Bioavailability was determined by dividing the individual
dose-normalized PO AUC values by the respective average dose-normalized intravenous (IV)
AUC value. Samples that were below the limit of quantification were not used in the calcula-
tion of averages, and were treated as zero for pharmacokinetic data analysis.
Stability and metabolism
For other stability and metabolite experiments, see Section C in S1 File.
Whole blood stability and metabolite profiling. C16 (1 μM) or vehicle (DMSO) were
incubated with fresh rat blood (Sprague Dawley, male) at 37˚C at 5 time points in duplicate
over a 120-min period. The final DMSO concentration in the incubation was 0.25%. Reactions
were terminated following 0, 15, 30, 60 and 120 min by acetonitrile containing internal stan-
dard. The sampling plate was centrifuged (3000 rpm, 45 min, 4 ˚C) and the supernatants from
each time point analyzed for parent compound by HPLC-MS/MS. The percentage of parent
compound remaining at each time point relative to the 0-min sample was then calculated from
HPLC-MS/MS peak area ratios (compound peak area/internal standard peak area).
Following the blood stability assay the time point at which 30–70% of parent had degraded
(15-min sample) was analyzed by HPLC-MS over a mass range of 200–1000 Da, using an
extended run time. Potential metabolites were identified by searching against expected bio-
transformations. Unexpected metabolites were also searched for by comparison to a control
sample (0-min time point and/or negative control) run under the same analysis conditions.
Metabolites had a ratio of at least two compared to a corresponding peak in the control
sample.
The metabolite sample was re-injected and data collected for the product ions in the mass
window of 50 Da to a point above the metabolite mass, with the precursor ion fixed on the
metabolite mass in the time window observed for the metabolite in the original chromato-
gram. MS/MS spectra of the metabolites were collected and processed into a table representing
product ion fragments for the parent and each metabolite.
Single-dose PO and IP MTD studies
Male ICR mice (20–26 g), were obtained from BioLASCO Taiwan. Animals were kept in con-
ventional cages with wood chip bedding. Space allocation for 3–5 animals was 30 x 19 x 13 cm.
All animals were healthy at the start of the trial and maintained in a well-controlled tempera-
ture (20–24˚C) and humidity (30%-70%) environment with 12 h light/dark cycles. Free access
to a standard lab diet [MFG (Oriental Yeast Co., Ltd., Japan)] and autoclaved tap water were
granted.
A single PO and IP dose progression test was conducted in which animals were dosed at a
minimum of 72- or 24-h intervals, respectively. C16 (vehicle: 10% Solutol HS-15 / 90% PEG
600) was administered by oral gavage at 10 mL/kg to randomly assigned groups of 2 male and
2 female mice, or by IP injection at 5 mL/kg to randomly assigned groups of 5 male mice. Ani-
mals received an initial dose of 10 mg/kg. If 50% of the animals survived for 72 h (PO) or 30
min (IP), the dose for the next cohort was increased. If one or more animals died, the dose for
the next cohort was decreased. The next dose level was determined by the decision scheme in
Fig 2.
The testing stopped when all animals survived at the upper bound, when four (PO) or three
(IP) dose levels had been tested or when the upper or lower bound had been reached. At each
dose level, animals were observed for the presence of acute toxic symptoms and autonomic
effects during the first 60 (PO) or 30 (IP) min, and again at 2, 6 (IP only), 24, 48 (PO only) and
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72 h (PO only). Body weights were recorded before dosing and at the 72- (PO) or 24-h (IP)
time point. Gross necropsy was performed in all animals without tissue collection.
7-Day repeat-dose toxicity study
Fifteen 7-week old male CD-1 mice, weighing 27 to 34 g, were obtained from Janvier, France.
Animals were randomly allocated to one of four cohorts (N = 4 for the 0 mg/kg, 100 mg/kg
and 300 mg/kg C16 cohorts, N = 3 for the water control group). Animals were healthy at the
start of the trial. Each cohort was housed in one conventional cage with wood chip bedding
and kept in a room with a well-controlled temperature (20–24˚C) and humidity with 12-h
light/dark cycles. Duration of acclimation was five days, during which all animals had ad libi-
tum access to feed and tap water. Feed was obtained from Carfil, Belgium (Complete feed for
rats and mice, article n˚ 10783915). Animals were ear-marked under isoflurane anesthesia
(induction 5%, maintenance 2.5%, oxygen 1 L/min) on day -3 of the study. The study was not
blinded.
Study design. On the morning of day -2 of the study, tap water access was removed from
the 0 mg/kg, 100 mg/kg and 300 mg/kg C16 cohorts. These groups were granted access to two
non-medicated cups of Medigel sucralose (one in a tailor-made plastic holder with magnetic
fixation system to the side of the cage, one in a cardboard holder on top of the bedding mate-
rial) for an acclimatization period of three days. Note: the magnetic fixation system is prefera-
ble, as animals tear and consume the cardboard holders.
Medicated gels were prepared in order to provide animals with a PO C16 dose equaling
oral gavage dosing at 0, 100 and 300 mg/kg three times per day (0, 78.43 and 235.29 mg C16
per cup, respectively, assuming a consumption of 7 mL of gel per day and an average animal
weight of 30 g). On the morning of day 0 of the study, treatment with two medicated gels was
started and maintained up to the morning of day 7 (i.e. a 7-day treatment). Fresh cups were
prepared and provided every day. Meanwhile, the water control group was continuously
granted unlimited access to tap water. Throughout the study, all animals had ad libitum access
to feed, except for the water control group, which was fasted on the evening of day 6, i.e. twelve
hours prior to the single PO test article administration. Animal weight, feed and water/gel con-
sumption and the presence of toxic symptoms and autonomic effects were monitored on a
daily basis for all cohorts.
On the evening of day 6, blood was collected via the tail vein for the 0, 100 and 300 mg/kg
C16 cohorts for determination of the whole blood C16 level. On the morning of day 7, mice of
Fig 2. Dose-level decision scheme for the PO and IP MTD studies.
https://doi.org/10.1371/journal.pone.0192548.g002
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the 0, 100 and 300 mg/kg C16 cohorts were anesthetized by IP injection with 250 mg/kg of
Avertin (20 mL/kg, preparation see Section E in S1 File). Blood for C16 determination and
hematological and biochemical analysis was collected via cardiac exsanguination (600 μL to 1
mL). Detailed analysis protocols are described below. Afterward, animals were sacrificed by
cervical dislocation.
On the morning of day 7, the water group received a single PO administration of 300 mg/
kg C16 (10 mL/kg) for high-dose PK evaluation, using a 30 mg/mL solution of C16 in 10%
Solutol HS-15 / 90% PEG 600 (prepared as described above). To that extent, blood was col-
lected via the tail vein at the 30 and 60 min time point, and via cardiac exsanguination after
180 min (protocol as for other cohorts). Samples for hematological and biochemical analysis
were also prepared. Afterward, animals were sacrificed by cervical dislocation.
All animals were necropsied and assessed for gross pathology. Liver, kidneys and spleen
weights were recorded, and fragments of these organs were fixed in a 4% formaldehyde solu-
tion and processed for microscopic evaluation.
Whole blood C16 determination. Blood samples (25 μL) were collected via the tail vein
or cardiac puncture (last time point). Blood was pipetted into a tube with 25 μL heparinized
water (1 μL of sodium heparin (1000 units/mL) + 24 μL water) within 30 seconds of collection.
The sample was pipetted up and down five times, immediately frozen on dry ice, and stored at
-60˚C to -80˚C until analysis.
Hematology and biochemical analysis. Cardiac puncture as described above afforded
0.6–1 mL of blood. Approximately 500 μL thereof was collected in a Greiner Bio 0.5 mL ethyl-
enediaminetetraacetic acid (EDTA) Eppendorf tube for hematological parameter determina-
tion and kept at room temperature. The remaining volume was collected in a regular
Eppendorf tube and allowed to clot completely at room temperature over 45 min. The tubes
were centrifuged at 1,900 x g (3000 rpm) and 4 ˚C for 10 min using a swinging bucket rotor.
The upper serum phase was transferred to a new tube with conical bottom. Care was taken not
to disturb the intermediate buffy coat layer. The serum samples were centrifuged at 16,000 x g
and 4 ˚C for 10 min in a fixed-angle rotor. The cleared supernatant was transferred to a new
tube without disturbing the pellet, affording 200–500 μL of serum. Samples were diluted to 500
μL with normal saline, flash frozen in liquid N2 and stored at -80 ˚C prior to analysis. Hemato-
logical analysis was conducted on an XE-5000 Automated Hematology System (Sysmex,
USA), biochemical analysis on a cobas 8000 series system (Hitachi/Roche, USA).
Results
Vehicle development
Vehicles for single-dose studies. C16 has low aqueous solubility, which limits the choice
of preclinical formulations for in vivo studies. In this work, thirteen vehicles were evaluated for
their applicability in single-dose studies (Table 1). For commonly used systems (entries a-e)
visual determination of solubility was conducted, while for the more complex systems solubil-
ity was assessed by laser nephelometry.
As expected, C16 proved highly soluble in DMSO (entry a). A more preferable formulation
with 25% DMSO in Cremophor and water (entry e) also proved suitable at low concentrations
(up to 2 mg/mL). These vehicles are appropriate for single-dose studies with low amounts of
C16, e.g. in PK studies. Dimethylacetamide / 90% PEG 600 and Solutol HS-15 / PEG 600 gave
clear solutions at 10 and 30 mg/mL (entries p,q and t,u). These potential high-dose vehicles
were further evaluated for tolerability and stability. Solutions of 10 and 30 mg/mL C16 in 10%
Solutol HS-15 / 90% PEG 600 proved stable at both room temperature (20–25 ˚C) and 4˚C
over 24 h (Fig 3, ANOVA/Tukey HSD or Welch/Gamess-Howell, Table A in S1 File). No
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adverse signs were elicited by both vehicles on PO administration (see section ‘Single dose PO
and IP MTD studies’). IP dosing of the more common of these two vehicles, Solutol HS-15 /
PEG 600, at 5 mL/kg induced mild adverse effects (decreased exploratory behavior, decreased
muscle tone) within 30 min after administration (see section ‘Single dose PO and IP MTD stud-
ies’, 10% DMA / 90% PEG 600 not tested). 10% Solutol HS-15 / 90% PEG 600 thus is a valid
vehicle for high-dose experiments, e.g. MTD studies.
Vehicle for repeat-dose studies. For repeated oral dosing over an extended period of
time, a formulation of C16 in medicated gel (Medigel Sucralose, ClearH2O) was developed as
an alternative to repeated oral gavage. Medigel Sucralose is a non-wetting sucralose-flavored,
low calorie water gel with a sweet taste. The chosen formulation as a medicated gel is a stable
suspension of C16 particles in water. The stability of this dispersion at room temperature was
confirmed over 144 h (Fig 4 and Tables C-D in S1 File), and the compound proved uniformly
distributed (see Table E in S1 File). The tolerability of Medigel Sucralose had been explored by
others [17]. Observations on the tolerability of DMSO in the gel (this co-solvent is used as a
solubilizing agent during preparation) are mentioned in the discussion of the repeat-dose tox-
icity test.
PK parameters of C16 in the rat and mouse
C16 plasma pharmacokinetics were determined in male Sprague-Dawley rats after intravenous
and oral administration at 1 and 10 mg/kg, respectively (Table 2, Fig 5A, Tables F-G and Figs
B-C in S1 File). In this exploratory experiment, C16 and two other (undisclosed) compounds




a DMSO 10 Soluble a
b 10% DMSO in normal saline 1 Insoluble a
c 50% DMSO in normal saline 1 Insoluble a
d 10% (DMSO / Cremophor EL 1:1) / 90% Milli-Q water 2 Insoluble a
e 20% DMSO / 10% (DMSO / Cremophor EL 1:1) / 70% Milli-Q water 2 Soluble a
f 10% Cremophor EL / 10% EtOH 10 Insoluble b
g 30 Insoluble b
h 10% DMA / 10% EtOH / 20% PG 10 Insoluble b
i 30 Insoluble b
j 10%DMA / 20%PG / 40% PEG 400 10 Insoluble b
k 30 Insoluble b
l 40% PEG 400 / 10% EtOH 10 Insoluble b
m 30 Insoluble b
n 20% PEG 400 / 10% Cremophor EL 10 Insoluble b
o 30 Insoluble b
p 10% Solutol HS-15 / 90% PEG 600 10 Soluble b
q 30 Soluble b
r 100% Corn oil 10 Insoluble b
s 30 Insoluble b
t 10% Dimethylacetamide (DMA) / 90% PEG 600 10 Soluble b
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were dosed in cassette in 100% DMSO. No adverse effects were observed after the intravenous
and oral administration of the materials. Following intravenous dosing of C16 at 1 mg/kg, a
c0 of 1257 ng/mL was reached with an average half-life of 1.93 h. The average clearance was
4.95 L/h/kg, the volume of distribution 4.77 L/kg. After oral dosing at 10 mg/kg, a cmax of 32.2
Fig 3. Stability of C16 in 10% Solutol HS-15 / 90% PEG 600 at 4 ˚C and room temperature (RT). Peak ratios of C16 versus IS are shown (ANOVA/Tukey HSD
or Welch/Gamess-Howell).
https://doi.org/10.1371/journal.pone.0192548.g003
Fig 4. Stability of a dispersion of C16 in Medigel Sucralose (235.29 mg/cup) containing 1.64% DMSO at room
temperature. Peak ratios of C16 and IS are displayed (average ± SD of 3 wavelengths: 220 nm, 254 nm and 280 nm).
https://doi.org/10.1371/journal.pone.0192548.g004
4-Fluoro-3’,4’,5’-trimethoxychalcone: Vehicle development, pharmacokinetics and toxicity
PLOS ONE | https://doi.org/10.1371/journal.pone.0192548 February 22, 2018 10 / 23
ng/mL and oral bioavailability of 6.91% was found. The half-life value of 3.67 h was longer
than that observed after IV administration.
Next, the whole-blood pharmacokinetics of C16 in male CD-1 mice were evaluated after
intravenous (1 mg/kg), intraperitoneal (IP, 10 mg/kg) or oral (PO, 10 mg/kg) administration
in cassette dosing with two other (undisclosed) compounds (Table 2, Fig 5B, Tables H-J and
Figs D-F in S1 File). In this experiment, 20% DMSO/10% (DMSO/Cremophor EL 1:1)/70%
H2O was used as a more preferable vehicle with respect to pure DMSO. No adverse reactions
Table 2. Average PK parameters of C16 in the mouse and the rat.
Plasma, male Sprague-Dawley rat Whole blood, male CD-1 mouse
IV PO IV IP PO
Dose (mg/kg) 1 a 10 a 1 b 10 b 10 b
c0 (ng/mL) c 1257 76.0
cmax (ng/mL) c 32.2 107 12.5
tmax (h) c 0 2.83 0 0.25 0.25
t1/2 (h) 1.93 3.67 f 0.746 0.800 ND
MRTlast (h) 0.76 3.67 0.433 0.800 1.38
CL (L/h/kg) 4.95 45.0 0.952
Vss (L/kg) 4.77 32.6
AUClast (hng/mL) 211 146 20.0 109 20.9
AUC1 (hng/mL) 215 161
f 22.4 114 ND
Dose-normalized values d
AUClast (hkg ng/mL/mg) 211 14.6 10.9 2.09
AUC1 (hkg ng/mL/mg) 215 16.1
f 11.4 ND
Bioavailability (%) e 6.91 54.7 10.5
c0: Maximum plasma concentration extrapolated to t = 0; cmax: Maximum plasma concentration; tmax: Time of maximum plasma concentration; t1/2: half-life; MRTlast:
Mean Residence Time, calculated to the last observable time point; CL: Clearance; Vss: Steady state volume of distribution; AUClast: Area under the curve, calculated to
the last observable time point; AUC1: Area under the curve, extrapolated to infinity; ND: not determined.
a Vehicle: DMSO.
b Vehicle: 20% DMSO/10% (DMSO/Cremophor EL 1:1)/70% H2O.
c Extrapolated to t = 0.
d Dose normalized by dividing the parameter by the nominal dose in mg/kg.
e Bioavailability determined by dividing the individual dose normalized oral AUC by the individual dose normalized intravenous AUC value;
f Calculated for two out of three animals.
https://doi.org/10.1371/journal.pone.0192548.t002
Fig 5. C16 Pharmacokinetics: Concentration-time curves. A: rat, plasma; B: mouse, whole blood.
https://doi.org/10.1371/journal.pone.0192548.g005
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were observed. Following intravenous (IV) dosing at 1 mg/kg, C16 had a half-life of 0.746 h, a
clearance rate of 45.0 L/h/kg, and a volume of distribution of 32.6 L/kg. Following IP and PO
dosing at 10 mg/kg, C16 reached a maximum blood concentration of 107 and 12.5 ng/mL,
respectively, both at 15 min post dosing. The average IP and PO bioavailability was 54.7% and
10.5%, respectively.
Stability and metabolism
Interpretation of the above PK data required the generation of additional in vitro stability and
metabolism data (Table 3), and revision of known data [5]. As illustrated above, solubility and
lipophilicity are acceptable for exploratory work in vivo when using suitable vehicles. C16 has
a high Caco-2 classification, with a discrepancy in recovery for the A!B and B!A-directions.
The compound is stable in simulated intestinal and gastric fluid and in PBS. A much higher
intrinsic clearance was obtained for rat liver microsomes in comparison with earlier results
for humans [5]. C16 does not significantly inhibit three major drug-drug interaction (DDI)-
inducing human cytochromes P450 (CYPs, 1A2, 2D6 and 3A4). Despite the high protein bind-
ing of 99%, C16 has a high blood-to-plasma ratio of 9.2. A remarkable difference in half-life in
rat plasma and whole blood was obtained. In the whole blood stability assay, comparison of
Table 3. In vitro physicochemical, stability and metabolism data.
Parameter Unit Value
Aqueous solubility a PBS, pH 7.4 μM 7.9
simulated intestinal fluid μM 2.4
simulated gastric fluid μM 9.1
LogD b,f 3.85
Protein binding and recovery b,g % 99–90
Permeability and recovery c,h A-B 10−6 cm/s—% 10.4–17
B-A 10−6 cm/s—% 4.9–66
Half-life PBS, pH 7.4 d min >240
simulated gastric fluid d min >60
simulated intestinal fluid d min >240
blood (rat, Sprague-Dawley) d min 6
plasma (rat, Sprague-Dawley) d min >120
liver microsomes (rat, Sprague-Dawley) e min 20
Intr. clearance liver microsomes (rat, Sprague-Dawley) e μL/min/mg 339
CYP inhibition 1A2 (CEC substrate) c % inhibition of control 36
2D6 (MFC substrate) c % inhibition of control -19
3A4 (BFC substrate) c % inhibition of control 27








f Partition coefficient n-octanol/PBS, pH 7.4;
g Human plasma;
h Caco-2, pH 7.4/7.4.
https://doi.org/10.1371/journal.pone.0192548.t003
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the 15-min sample against the 0-min control revealed one major metabolite (Table 4, Tables
M-P in S1 File). HPLC-MS/MS profiling showed that this compound had the mass of a
C16-glutathione conjugate. Remarkably, also the Z-isomer of C16 was detected in this experi-
ment. Fast partial isomerization apparently occurred under the conditions of this experiment,
as the configuration of C16 was initially purely E (confirmed by nuclear magnetic resonance
(NMR) analysis). This isomerization was also observed after prolonged dissolution in Medigel
Sucralose (see below and Table C in S1 File). A similar isomerization was also made by Gutter-
idge et al. for two other chalcones [18]. Both the E- and Z-isomer of C16 showed a comparable
short half-life in rat whole blood. The extent to which this isomerization occurs in vivo is
unknown, yet it does not cause tolerability issues (see below).
Single-dose PO and IP MTD study
The MTD of C16 in mice, using 10% Solutol HS-15 / 90% PEG 600 as a high-dose vehicle, was
determined for both PO and IP administration. PO administration (oral gavage) was evaluated
in male and female ICR mice (N = 2 per group) using a starting dose of 10 mg/kg. The com-
pound was tolerated at 10–300 mg/kg though mild adverse effects such as vocalization and
increase in sensitivity to touch were observed at 100 and 300 mg/kg (Table 5, see also Section
D in S1 File). All animals survived during the 72-h observation period and no gross lesions
were discovered after necropsy. Body weight gain was not affected between cohorts of the
same sex (Gamess-Howell).
C16 was also administered intraperitoneally (IP) to a group of 5 male ICR mice. The vehicle
10% Solutol HS-15 / 90% PEG 600 at 5 mL/kg induced adverse effects such as decreased
exploratory behavior and decreased muscle tone within 30 min after administration (Table 6
Table 4. Parent/metabolite areas and percentage in 0 min control and 15 min samples.
Area in sample (%)
0 min control 15 min sample
C16 62.4 52.2
Z-isomer 36.5 10.7
Glutathione conjugate 1.06 37.1
https://doi.org/10.1371/journal.pone.0192548.t004
Table 5. MTD study in mice, PO administration: Observations.
Treatment Vehicle a C16
10 mL/kg 10 mg/kg 30 mg/kg 100 mg/kg 300 mg/kg
Sex M F M F M F M F M F
Behavioral b,c none none none none none none Yes: A,C Yes: B,C Yes: A Yes: A
Neurologic c none none none none none none none none none none
Autonomic c none none none none none none none none none none
Deaths 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
Necropsy: gross findings d none none none none none none none none none none
Weigt increase (%) e 21±0 4±6 25±3 2±3 18±3 6±3 25±1 8±1 17±0 7±3
a Vehicle: 10% Solutol HS-15 / 90% PEG 600.
b Behavioral changes: A: Irritability: vocalization, 1/2; B: Irritability: vocalization, 2/2; C: Slightly increased touch, 1/2.
c Observations made over the first 60 min.
d Necropsy 72 h post dosing.
e Over 72 h (average±SD)
https://doi.org/10.1371/journal.pone.0192548.t005
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and Section D in S1 File). Additional effects such as decreased sensitivity to touch, decreased
exploratory behavior, decreased spontaneous activity, decreased muscle tone, deep respiration,
decreased palpebral size and hunch back were elicited by C16 at the three doses levels (10, 30
and 50 mg/kg), with more severe effects observed at higher doses. The effects were reversible,
and all animals survived without significant changes in food consumption across groups
(Kruskal-Wallis) and with moderate weight decrease during the 24-hour experimental period.
Only between the 10 and 50 mg/kg cohorts, a significant difference in average weight decrease
was noted (p = 0.037, Kruskal-Wallis). In addition, no significant changes were observed dur-
ing gross necropsy.
Repeat-dose toxicity study
Finally, an assessment was conducted of the suitability of the medicated gel as a vehicle for oral
delivery, and of the toxicity of C16 on continuous dosing via this route of administration. Ani-
mals were given the equivalent of ter in die (TID, three times per day) dosing of 0, 100 and 300
mg/kg of C16 in Medigel Sucralose (1.64% DMSO) over a 7-day period. The 300 mg/kg value
was chosen as it was the highest evaluated dose in the single-dose MTD study. As a control, a
fourth cohort received regular drinking water during the same period. Overall, the Medigel
Table 6. MTD study in mice, IP administration: Observations.
Treatment Vehicle a C16
5 mL/kg 10 mg/kg 30 mg/kg 50 mg/kg
Behavioral b,c
Irritability: vocalization 0/5 0/5 1/5, ± 1/5, ±
Decreased touch response 1/5, ± 3/5, ± 5/5, ± 5/5, ±
Decreased exploration 3/5, ± 2/5, ± 3/5, ± 3/5, ±
Pinna 0/5 0/5 2/5, ± 2/5, ±
Neurologic b,c
Tremor: twitches 1/5 2/5 2/5 3/5
Decreased spontaneous activity 1/5, ± 3/5, ± 4/5, ± 5/5, ±
Ataxia 2/5, ± 2/5, ± 3/5, ± 2/5, ±
Low limb post 0/5 0/5 1/5, ± 2/5, ±
Abdominal tone 4/5, ±; 1/5, + 1/5, ±; 4/5, + 2/5, ±; 3/5, + 3/5, ±; 2/5, +
Limb tone 2/5, ±; 3/5, + 1/5, ±; 4/5, + 2/5, ±; 3/5, + 5/5, +
Grip strength 5/5, ± 4/5, ± 3/5, ±; 1/5, + 5/5, ±
Autonomic b,c
Respiration: depth 3/5, ± 3/5, ± 5/5, ± 3/5, ±
Low body temperature 0/5 0/5 0/5 5/5, ±
Decreased palpebral size 0/5 2/5, ± 4/5, ±; 1/5, + 5/5, ±
Hunch back 0/5 3/5 5/5 5/5
Deaths 0/5 0/5 0/5 0/5
Necropsy: gross findings d none none none none
Weigt decrease (%) e 5.1 2.4 4.8 8.7
±: slight to moderate; +: severe;
a Vehicle: 10% Solutol HS-15 / 90% PEG 600.
b For all observed criteria, see Table U in S1 File.
c Observations made over the first 30 min.
d Necropsy 24 h post dosing.
e Over 24 h (average±SD).
https://doi.org/10.1371/journal.pone.0192548.t006
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vehicle and compound were well-tolerated (raw data is available in Section E in S1 File). All
animals survived during the 7-day observation period.
As seen in the single-dose MTD study, mild behavioral changes were observed in the
C16-treated cohorts. From day 2 on, animals exhibited hyperactivity and increased anxiety on
opening of the cages. This behavior was absent in the 0 mg/kg and the water groups. The
effects were mild, ranging from slightly noticeable in the 100 mg/kg cohort to noticeable in the
300 mg/kg cohort. The magnitude of these effects did not increase in time. No significant dif-
ference in average weight between the four cohorts was noted during the study (Fig 6A, Tukey
HSD or Kruskal-Wallis). A slight but non-significant decrease in weight was observed during
the acclimatization period for all three Medigel cohorts with respect to the water cohort, indi-
cating slight neophobia towards the non-medicated gel. Animals recovered fast from day 0–1
on, despite the start of the treatment (no neophobia towards C16 or DMSO). Average food
intake per animal was around 6 g/day with a slight upward trend over the test period in all
cohorts (Fig 6B). Throughout the study, no significant differences in average food consump-
tion were observed between study groups (Tukey HSD) [19]. Decrease of gel per day was
between 8 and 16 g/animal, and did not differ significantly between the gel cohorts (Fig 6C,
Tukey HSD). An identical, slowly increasing trend in consumption was observed. The actual
gel consumption lies a fraction lower than the reported amounts because of loss of gel due to
sanitation of the cups pre-weighing. We estimate that the actual consumption will be close to
that of the water cohort, which is commensurate with the manufacturer’s findings [20].
No gross lesions were discovered on detailed necropsy. Liver and spleen weights were identi-
cal across the Medigel-treated cohorts, while a slight but significant decrease in kidney weight
was noted for the 300 mg/kg cohort with respect to the 100 mg/kg and to the 0 mg/kg cohort
(Fig 6D, ANOVA with post-hoc Tukey HSD, p = 0.001). No comparison was made with the
water cohort, since these animals were fasted overnight prior to necropsy. Histology of the kid-
ney and spleen revealed no abnormalities. A slight hepatocyte toxicity (centrilobular) was noted
in some animals of the Medigel-treated groups, but not in the water cohort (Fig 6E & 6F).
Clinical chemistry and hematology parameters were determined in all cohorts at the end of
the study (Table 7). All measurements fell within or were close to normal ranges (see Table Z
in S1 File). A (marginally) statistically significant difference between cohorts was only noted
for the glucose measurements of the treatment groups versus the blank. This result was
expected, since only the blank animals were fasted overnight prior to analysis.
On the last evening (day 6) and last morning (day 7) of the study, blood samples were taken
from the Medigel-treated cohorts to determine the systemic availability of C16 via this route of
administration. At both time points, whole blood C16 concentrations were above its projected
EC50 (Fig 7). No difference was found in C16 levels between the 100 mg/kg and 300 mg/kg
cohort, in both the evening (ANOVA) and morning (Mann-Whitney U test) samples. As
expected from their dietary pattern, average C16 levels were higher in the morning than in the
evening. Nevertheless, this difference was not statistically significant for the 100 mg/kg cohort
(p = 0.200, Mann-Whitney U test) and only borderline significant for the 300 mg/kg group
(p = 0.057, Mann-Whitney U test).
A final aspect of this 7-day study was a comparison between attainable plasma levels of C16
on administration via gel and oral gavage. On the final morning of the study, animals in the
water cohort received a single PO administration of 300 mg/kg of C16 in 10% Solutol HS-15 /
90% PEG 600 via oral gavage. Blood samples were collected after 30 min, 1 h and 3 h (Fig 8).
Maximum attainable concentrations via this route of administration were not higher than via
the medicated gel. Extrapolation of the time-concentration curve obtained for oral gavage
reveals the need for a dosing frequency of at least three times per day in order to obtain sus-
tained levels above the projected EC50 of the compound.
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Discussion
4-Fluoro-3’,4’,5’-trimethoxychalcone or C16 is a small molecule with nanomolar anti-invasive
activity, a defined structure-activity relationship and a satisfactory ADME and toxicity profile
in vitro [5–9]. In order to examine its potential as a pharmacological tool, prior exploration of
Fig 6. Selection of parameters recorded during the repeat-dose toxicity study. A. Animal weight (ANOVA, Kruskal-Wallis, error bars were omitted for clarity,
see Table V in S1 File). B. Feed consumption (Tukey HSD). C. Daily gel or water consumption (Tukey HSD). D. Average organ weights ±SD (ANOVA with post-
hoc Tukey HSD; p = 0.001). E. Hepatocyte toxicity, 0 mg/kg cohort animal. F. Normal hepatocytes, 300 mg/kg cohort animal.
https://doi.org/10.1371/journal.pone.0192548.g006
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its in vivo pharmacokinetic profile, toxicity and tolerability was required. The obtained data is
also relevant to several other members of the chalcone chemical class, which have been attrib-
uted biological activities (mostly at elevated concentrations) [11], but for which associated
DMPK profiling is lacking.
Vehicle development
DMSO is an excellent solvent for C16 but its applicability in vivo is limited. Other formulations
were therefore evaluated. For low single dose studies, DMSO/Cremophor/water was identified
as a suitable vehicle, while for high single-dose evaluation, Solutol HS-15 / PEG 600 proved
appropriate. C16 is stable when dissolved in Solutol HS-15 / PEG 600, and the vehicle is well
tolerated in the mouse when given via oral gavage. It however generated moderate adverse
effects on IP administration, which prohibits its IP use in chronic dosing studies.
Table 7. Clinical chemistry and hematology results after 7-day continuous PO dosing via medicated gels versus
the water control group(average±SD).
Parameter Cohort
0 mg/kg 100 mg/kg 300 mg/kg water
Clinical chemistry
ALP (IU/L) 92±12 118±33 94±18 93±14
ALT (IU/L) 43±19 70±40 43±9 78±36
AST (IU/L) 188±84 345±365 221±65 466±387
CHO (mg/dL) 91±17 96±21 73±18 91±8
GLUC (mg/dL)  ,a 206±11 a 218±30  206±24 a 136±57
TP (g/L) 37.8±1.0 42.0±4.5 31.6±21.3 45.7±3.6
TRIGL (mg/dL) 207±79 110±45 123±55 108±21
Hematology
WBC (103/μL) 3.02±0.77 3.05±0.08 2.97±0.94 1.62
RBC (106/μL) 7.02±1.40 8.32±0.69 6.32±1.92 8.09
HGB (g/dL) 11.3±2.0 12.2±0.2 10.1±2.9 13
HCT (%) 37.7±7.1 44.5±5.2 34.0±7.78 40.9
MCV (fL) 53.8±0.6 53.4±1.8 54.5±4.24 50.6
MCH (pg) 16.2±0.4 14.7±1.5 16.0±0.2 16.1
PLT (103/μL) 258±41 281±33 2665±12 338
NEUT (%) 28.6±4.7 16.9±4.9 39.9 43.2
LYMP (%) 65.4±9.9 79.2±3.4 60.1 56.8
MONO (%) 1.4±1.3 2.5±0.6 2.6±3.7 0
EO (%) 0.4±0.5 0±0 0±0 0
BASO (%) 0.08±0.2 0.2±0.2 0±0 0
NRBC (103/μL) 0±0 0.75±1.06 0.35±0.49 1.2
IG (103/μL) 0±0 0.04±0.06 0 0
Abbreviations: WBC: white blood cells; RBC: red blood cells; HGB: hemoglobin; HCT: hematocrit; MCV: Mean
corpuscular volume; MCH: Mean corpuscular hemoglobin; PLT: platelets; PCT: platelet hematorcrit; ALP: alkaline
phosphatase; ALT: alanine transaminase; AST: aspartate transaminase; CHO: cholesterol;; GLUC: glucose; IG:
immature granulocytes; NRBC: nucleated red blood cells; TP: total protein; TRIGL: triglicerides;
 Significant difference in glucose level between 100 mg/kg and water cohort (p = 0.028);
a Marginally significant difference between 0 mg/kg and blank cohort (p = 0.062), and between 300 mg/kg and blank
cohort (p = 0.063).
https://doi.org/10.1371/journal.pone.0192548.t007
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The suboptimal DMPK properties of C16 (see below) would necessitate at least three oral
gavage administrations per day to maintain the desired plasma levels in chronic experiments.
We therefore turned to self-medication, as this reduces animal handling and stress, and does
not disrupt the diurnal rhythm of the animals. It also reduces the burden on the investigator
significantly. Administration of C16 via regular drinking water was not possible, as the com-
pound crashes out of solution and moreover is unstable in an aqueous environment upon
Fig 7. Whole blood levels of C16 after 7-day continuous PO dosing via medicated gels and comparison with
projected C16 EC50 value (10 nM or 6.32 ng/mL). N = 4, except for the 300 mg/kg evening condition (N = 3).
Respectively 2 and 3 animals had C16 levels below the limit of quantification in the 0 mg/kg evening and morning
conditions. Statistics: ANOVA or Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0192548.g007
Fig 8. Concentration-time curve for C16 on dosing via oral gavage at 300 mg/kg in the mouse.
https://doi.org/10.1371/journal.pone.0192548.g008
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prolonged dissolution. At the start of this study, a limited number of reports on the use of
medicated gels as a route of administration were available. Medicated gels have advantages
over mixing in the feed, as new batches can be prepared on a flexible basis and without the
need for special equipment. Daily gel intake is comparable to that of regular drinking water,
the gel can thus serve as a complete replacement of drinking water over prolonged periods of
time. A major aim of this study was the development of a C16-doped gel as a vehicle for
chronic dosing. A suitable formulation was developed in the form of a stable suspension of
C16 in Medigel Sucralose. The compound proved stable in this preparation over 144 h, and
was shown to be uniformly spread. Earlier reports had validated the tolerability of Medigel
Sucralose in rodents. Validation of C16-doped Medigel Sucralose for use in mice was con-
ducted in a repeat-dose toxicity study (described below).
Pharmacokinetics
The IV, IP and PO pharmacokinetic profile of C16 was determined in rat plasma and mouse
whole blood. Regardless of the vehicle (DMSO or DMSO/Cremophor/water), sampling
(plasma or whole blood) and species (rat or mouse), the compound shows low (PO) to moder-
ate (IP) bioavailability. In both cases, slow dissolution is a limiting factor, resulting in a similar
tmax for IP and PO dosing, prolonged exposure and rather flat (rat) or multiple peak (mouse)
concentration-time profiles on PO dosing. The use of cassette dosing may have accentuated
this phenomenon, though the main cause can be found in the physicochemical profile of C16.
It should be noted that the significance of the average tmax for PO dosing in rats is limited, as a
flat average concentration-time profile was obtained. Despite its good permeability, the low
A!B recovery of C16 in the Caco-2 assay suggests cellular metabolism, which also limits oral
bioavailability. While the high extent of protein binding may also necessitate elevated oral dos-
ing, the high recovery levels suggest reversible binding.
Regardless of the sampling mode (plasma or whole blood), both rat and mouse half-life on
IV dosing are short. This is in line with data published for other chalcones [13]. Nevertheless,
an important difference in initially attained IV concentrations was noted, which can be attrib-
uted to species and sampling factors. Clearance in both species is much higher than hepatic
blood flow (rat: 3.3 L/h/kg, mouse: 5.4 L/h/kg), which points towards extra-hepatic elimina-
tion. C16 shows high apparent blood partitioning and a large difference between plasma and
whole blood half-life. Rather than irreversible binding to erythrocytes, the compound was
found to be metabolized rapidly with glutathione conjugation as the major mechanism. Eryth-
rocytes are a major site of biotransformation and contain cytosolic glutathione S-transferases
[21]. The conjugates are then actively transported outward across the red-cell membrane [22].
Metabolism in red blood cells thus seems the major route of extra-hepatic elimination for C16,
explaining its much shorter half-life in blood versus plasma. This route of metabolism was not
observed for other rapidly metabolized chalcones such as cardamonin [14]. As a further conse-
quence, the higher reported blood-to-plasma ratio is not accurate because it was not based on
measurements of both blood and plasma fractions.
Tolerability, toxicity and chronic systemic availability
The maximum tolerated single dose of C16 in the mouse on administration via oral gavage is
>300 mg/kg. The compound was well tolerated, and induced only mild behavioral effects at
100 and 300 mg/kg (vocalization and increased sensitivity to touch). The pre-defined humane
end points (see Methods section) were not reached. No other treatment-induced phenomena
were noted on observation or necropsy. The animals proved much more sensitive to intraperi-
toneal delivery of a single dose of the same vehicle and compound, though humane end points
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were again not reached. These observations can be correlated to a low tolerability of the vehicle
itself, and the earlier observed higher Cmax for C16 on IP delivery with respect to oral adminis-
tration (Table 2). Moderate to severe behavioral, neurologic and autonomic effects were noted
in a dose-response pattern. These results indicate that the vehicle and C16 up to 50 mg/kg may
be tolerated for single-dose IP administration in the mouse, but not for chronic experiments.
Despite its low oral bioavailability, the high oral tolerability of C16 offers opportunities to
obtain sufficiently high systemic levels for efficacy testing. This hypothesis was tested in a
repeat-dose experiment. The 7-day continuous dosing experiment validated Medigel sucralose
as a vehicle for self-medication of C16 in a chronic setting. Substitution of drinking water for
blank gels caused a slight but non-significant decrease in weight during the acclimatization
period due to neophobia. During the further course of the experiment, however, treatment
with solvent-doped gels (DMSO) did not generate significant differences in weight, water and
food intake, and hematological and biochemical parameters with respect to the water cohort.
No gross lesions or differences in organ weights were noted on necropsy. A slight hepatocyte
toxicity, however, was noted for some gel-treated animals, which was absent in the water
cohort. This effect may be due to the relatively high DMSO content of the gel. DMSO hepato-
toxicity has been reported in chronic trials in laboratory animals [23–26]. In our setting the
effect was not major, nor is it reflected in the clinical chemistry panel. The DMSO dose was
also well below the LD50 in the mouse (21–28 g/kg, PO) [25,27]. Overall, Medigel Sucralose
thus proved a suitable vehicle for chronic studies.
Oral C16 dosing via medicated gels over a 7-day period caused sustained systemic levels
above its projected EC50 value (6.32 ng/mL). This is a significant result, as a major reason for
poor correlation between in vitro and in vivo efficacy of chalcones has been their poor pharma-
cokinetics and bioavailability, yielding plasma levels below the EC50 of the compounds [18].
Gel intake was close to the anticipated amount for all cohorts, resulting in an actual daily oral
dose close to the intended. C16 showed nonlinear uptake as systemic levels did not differ sig-
nificantly between the 100 mg/kg and 300 mg/kg cohort. Given the physicochemical profile of
C16, this is likely due to limits in dissolution. Lower dosing regimens may thus still generate
sufficient systemic levels, but were not evaluated in this work. Importantly, as expected from
the low-dose PK studies, the high-dose concentration-time profile obtained after a single
administration of 300 mg/kg C16 via oral gavage confirms the need for TID dosing in order to
reach sustained levels above the EC50. This underpins the value of the developed medicated gel
formulation in the present research and for others working on related molecules.
The confirmed seven-day exposure to the molecule at levels above its EC50 did not engen-
der treatment-associated differences between the 0, 100 and 300 mg/kg cohorts, except for a
slightly lower kidney weight in the 300 mg/kg cohort. Nephrotoxicity was however not
detected in any of the cohorts during histological examination. Hematological parameters
were all satisfactory. Some individual measurements fall slightly outside of reported reference
ranges, but these ranges itself vary strongly upon the cited source and underlying animal-
related variables. The only valid comparison of therapy response thus is to the age-, strain-,
and sex-matched controls of the water cohort [28]. No differences were found, except for a
lower average glucose reading in the water cohort due to fasting prior to sampling.
Oral delivery using our medicated gel formulation thus is a suitable tool for evaluating the
efficacy of C16 in a range of invasion and metastasis models. Depending on the models and
more specifically on the interrogated phenomena (local invasion, regional or distal metastasis),
compatible dosing schedules may include prophylactic treatment over a 7-day period before
inoculation (e.g. in a peritoneal metastasis model), intermittent or low-dose chronic treatment
in long-term experiments (months) or high-dose treatment in short-term, more aggressive
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models (weeks) [29–31]. From the data gathered in this report, adequate exposure and good
tolerability of C16 can be expected in these settings.
Conclusions
C16, like other members of the chalcone family [13,14], shows suboptimal pharmacokinetics
in the rat and the mouse. Its limited solubility and cellular metabolism causes poor intestinal
uptake and limited oral bioavailability. The compound is rapidly metabolized, with a clearance
rate exceeding hepatic blood flow. Glutathione conjugation in erythrocytes was identified as a
major route of extra-hepatic elimination, explaining the much shorter half-life of C16 in blood
versus plasma. An oral dosing routine using medicated gels was developed that solved these
issues. A schedule providing amounts equivalent to oral gavage at 100 mg/kg three times per
day yielded sustained whole blood levels above the EC50 in a 7-day chronic study. The com-
pound showed good tolerability during the latter experiment. Evaluation of C16 as a pharma-
cological tool in animal models of metastatic disease, using the medicated gel formulation, is
currently ongoing. Besides, we are preparing analogs with a superior DMPK profile in search
of improved clinical relevance.
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